Blood test may spot hidden breast cancer months before scans

NCT ID NCT07478705

Not yet recruiting Diagnosis Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing every 3 months. If the blood test shows signs of cancer, they will get extra scans. The goal is to see if this approach is practical for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ctDNA blood test
What this could lead to: If successful, this approach could help detect cancer return months earlier, potentially leading to better treatment outcomes and longer survival for patients with triple-negative breast cancer.
What could go wrong: This is a very small pilot study (30 people) testing feasibility, not yet proving that earlier detection improves survival. It may not lead to clear benefits and could cause unnecessary anxiety or scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTDNA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Recurrence triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTDNA RECURRENCE SURVEILLANCE TRIPLE NEGATIVE BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.